**Analysis:**
The Johnson & Johnson (J&J) Q1 2014 earnings call highlights strong performance across all business segments, with notable growth in pharma, driven by new product launches and market growth. The company's guidance for 2014 is also positive, with an expected increase in sales and EPS, despite currency exchange rate headwinds. The call also addresses strategic initiatives, including the sale of the Ortho-Clinical Diagnostics business and the divestiture of the K-Y brand. Overall, the earnings call provides a positive outlook for the company, with growth expected to continue throughout the year.

**Conclusion:**
The short-term (1â€“2 weeks) impact on the stock price is expected to be positive due to the company's strong Q1 performance and positive guidance for the year. The stock is likely to rally as investors react to the positive news and the company's strategic initiatives. The rating for the short-term impact on the stock price is:

**Rating: 1**